T-Cell Therapy: Options for Infectious Diseases
The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8+ and CD4+ T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
|---|---|
| Enthalten in: |
Clinical Infectious Diseases - 61(2015) vom: Okt., Seite S217-S224 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Parida, Shreemanta K. [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: | |
|---|---|
| Themen: |
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
JST128342811 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | JST128342811 | ||
| 003 | DE-627 | ||
| 005 | 20230504234450.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210701s2015 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)JST128342811 | ||
| 035 | |a (JST)26369032 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Parida, Shreemanta K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a T-Cell Therapy: Options for Infectious Diseases |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The emergence of drug-resistant tuberculosis is challenging tuberculosis control worldwide. In the absence of an effective vaccine to prevent primary infection with Mycobacterium tuberculosis and tuberculosis disease, host-directed therapies may offer therapeutic options, particularly for patients with multidrug-resistant and extensively drug-resistant tuberculosis where prognosis is often limited. CD8+ and CD4+ T cells mediate antigen-specific adaptive cellular immune responses. Their use in precision immunotherapy in clinical conditions, especially in treating cancer as well as for prevention of life-threatening viral infections in allogeneic transplant recipients, demonstrated safety and clinical efficacy. We review key achievements in T-cell therapy, including the use of recombinant immune recognition molecules (eg, T-cell receptors and CD19 chimeric antigen receptors), and discuss its potential in the clinical management of patients with drug-resistant and refractory tuberculosis failing conventional therapy. | ||
| 655 | 4 | |a research-article | |
| 700 | 1 | |a Poiret, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Zhenjiang, Liu |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Qingda |e verfasserin |4 aut | |
| 700 | 1 | |a Heyckendorf, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Lange, Christoph |e verfasserin |4 aut | |
| 700 | 1 | |a Ambati, Aditya S. |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Martin V. |e verfasserin |4 aut | |
| 700 | 1 | |a Valentini, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrara, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Rangelova, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Dodoo, Ernest |e verfasserin |4 aut | |
| 700 | 1 | |a Zumla, Alimuddin |e verfasserin |4 aut | |
| 700 | 1 | |a Maeurer, Markus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i in |t Clinical Infectious Diseases |d Oxford University Press, 1992 |g 61(2015) vom: Okt., Seite S217-S224 |w (DE-627)JST025522906 |x 15376591 |7 nnns |
| 773 | 1 | 8 | |g volume:61 |g year:2015 |g month:10 |g pages:S217-S224 |
| 856 | 4 | 0 | |u https://www.jstor.org/stable/26369032 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_JST | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.75 |q ASE |
| 951 | |a AR | ||
| 952 | |d 61 |j 2015 |c 10 |h S217-S224 | ||